Novel 2-substituted ergolinyl urea and thioruea derivatives are disclosed, as well as their use as pharmaceuticals, specifically as neuroleptics. The compounds, which possess central dopaminergic activity, have the formula <IMAGE> (I) wherein X is an oxygen or sulfur atom, R1 is a lower alkyl group, Y is a sulfur atom, S-CH2-, C2H4-, -CH=CH-, or -C 3BOND C-, R2 is an aromatic ring of 5-6 atoms, 0-3 of which are O, S or N; or an aromatic ring of 5-6 atoms, 0-3 of which are O, S or N, and which is substituted by C1-2-alkyl, C1-2-alkoxy, nitrile, nitro, amino, C1-2-alkylamino, carbonylamino or halo group, and C9C10 is a CC-single or a CC-double bond and, if C9C10 means a CC-single bond, the hydrogen atom in the 10-position is in the alpha -location, or a pharmaceutically acceptable acid addition salt thereof, wherein, if X is an oxygen atom, R1 is methyl and C9C10 is a single bond, Y-R2 does not mean -C2H4-phenyl or -C 3BOND C-phenyl.
2-substituted ergoline urea and thio-urea derivatives having neurolyptic/dopaminergic activity